Development of PRS-220, a potential best-in-class, inhaled CTGF/CCN2 inhibitor for the treatment of IPFVanessa Welk, Shane A. Olwill, Marina Pavlidou et al.|Unknown|2021Cited by 3
Abstract LB220: The anticalin-antibody bispecific PRS-352/S095025 strongly stimulates human CD4+ T cells in a PD-L1-dependent mannerLucia Pattarini, Shane A. Olwill, Marina Pavlidou et al.|Cancer Research|2022Cited by 2
Abstract LB135: Simultaneous costimulatory T-cell engagement and checkpoint inhibition by PRS-344/S095012, a PD-L1/4-1BB bispecific compound for tumor localized activation of the immune systemAizea Morales‐Kastresana, Shane A. Olwill, Véronique Blanc et al.|Cancer Research|2021Cited by 1
Supplementary Table from The PD-L1/4-1BB Bispecific Antibody–Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized MannerJanet K. Peper-Gabriel, Shane A. Olwill, Marina Pavlidou et al.|Unknown|2023Cited by 1
Supplementary Figure from The PD-L1/4-1BB Bispecific Antibody–Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized MannerJanet K. Peper-Gabriel, Shane A. Olwill, Marina Pavlidou et al.|Unknown|2023Cited by 0